Chunmei Tian1, Lin Zhang2, Xiaohua Li1, Yanjun Zhang1, Jianchang Li1, Liang Chen2. 1. Department of Pediatrics, Affiliated Hospital of Binzhou Medical University, Binzhou 256603, Shandong, China. 2. Department of Radiology, Affiliated Hospital of Binzhou Medical University, Binzhou 256603, Shandong, China.
Abstract
BACKGROUND: Abnormal expression of miR-192 has been observed in a variety of human cancers, but the expression pattern of miR-192 and its prognostic value in pediatric acute myeloid leukemia (AML) is poorly known. OBJECTIVE: This study was to explore the expression status of miR-192 and its clinical significance in pediatric patients with AML. METHODS: Quantitative RT-PCR was carried out to detect miR-192 expression level in the serum from 97 AML cases and 50 healthy controls. RESULTS: The results showed that downregulation of serum miR-192 was observed in pediatric AML patients and strongly correlated with aggressive clinical features. Increased serum miR-192 expression occurred more frequently in the AML subjects with favorable risk cytogenetics. Moreover, serum miR-192 expression showed good performance to screen pediatric AML subjects from normal controls. Furthermore, serum miR-192 was identified as a independent prognostic indicator for both overall survival and event free survival. In addition, low serum miR-192 expression significantly contributed to poor prognosis in the whole cohort of AML patients or the AML patients with intermediate-risk cytogenetics. CONCLUSIONS: Collectively, serum miR-192 potentially can be a reliable biomarker for the diagnosis and prognosis in pediatric AML.
BACKGROUND: Abnormal expression of miR-192 has been observed in a variety of humancancers, but the expression pattern of miR-192 and its prognostic value in pediatric acute myeloid leukemia (AML) is poorly known. OBJECTIVE: This study was to explore the expression status of miR-192 and its clinical significance in pediatric patients with AML. METHODS: Quantitative RT-PCR was carried out to detect miR-192 expression level in the serum from 97 AML cases and 50 healthy controls. RESULTS: The results showed that downregulation of serum miR-192 was observed in pediatric AMLpatients and strongly correlated with aggressive clinical features. Increased serum miR-192 expression occurred more frequently in the AML subjects with favorable risk cytogenetics. Moreover, serum miR-192 expression showed good performance to screen pediatric AML subjects from normal controls. Furthermore, serum miR-192 was identified as a independent prognostic indicator for both overall survival and event free survival. In addition, low serum miR-192 expression significantly contributed to poor prognosis in the whole cohort of AMLpatients or the AMLpatients with intermediate-risk cytogenetics. CONCLUSIONS: Collectively, serum miR-192 potentially can be a reliable biomarker for the diagnosis and prognosis in pediatric AML.
Authors: Patrick Nylund; Alba Atienza Párraga; Jakob Haglöf; Elke De Bruyne; Eline Menu; Berta Garrido-Zabala; Anqi Ma; Jian Jin; Fredrik Öberg; Karin Vanderkerken; Antonia Kalushkova; Helena Jernberg-Wiklund Journal: Cell Death Dis Date: 2021-02-12 Impact factor: 8.469